Phase I Dose-Escalating and Phase II Dose-Expansion Study of N-Acetyl-Cysteine (NAC) Administration to Ovarian Cancer Patients Receiving Platinum-Based Therapy (PBT) for the Mitigation of Chemotherapy-Related Cognitive Impairment (CRCI)

This is a phase I, dose-escalation and phase II dose-expansion clinical trial determining the maximum tolerated dose (MTD) and safety and tolerability of adding N-Acetyl-Cysteine (NAC) to ovarian cancer patients who are receiving a platinum-based therapy (PBT). This study will investigate whether NAC will mitigate chemotherapy-related cognitive impairment (CRCI).

Start Date01 Dec 2025

Sponsor / Collaborator

University of California, Irvine

[+1]

NCT04381897

/ Not yet recruitingPhase 2IIT

Use of N-Acetylcysteine (NAC) in the Treatment of Repetitive Behaviors (RB) and Self-Injurious Behaviors (SIB) in Cornelia de Lange Syndrome: A Randomized Double-Blind Placebo-Controlled Pilot Study

This research project is a randomized cross-over pilot trial which aims to test the efficacy of N-acetylcysteine (NAC) for the treatment of Repetitive Behaviors (RB) and self-injurious behavior (SIB) in patients with Cornelia de Lange Syndrome (CdLs).
NAC is a known anti-oxidative stress and neuroprotective agent, which has been shown to decrease the occurrence of SIB such as skin picking. NAC has also shown partial response in trials for compulsive behaviors in Obsessive Compulsive Disorder (OCD) and related disorders in autism.
Cornelia de Lange syndrome (CdLS) is a genetic disorder with autistic features, including RBs and SIB. In this randomized clinical trial, participants with CdLS will be blindly assigned one of two possible treatment arms: 1) placebo (8 weeks) and NAC (8 weeks); or 2) NAC (8 weeks) and placebo (8 weeks), with an intermediate 2-week washout period.

Start Date01 Oct 2025

Sponsor / Collaborator

The Johns Hopkins University

NCT06890507

/ Not yet recruitingPhase 2IIT

The Anti-Anginal Effects of N-Acetylcysteine (NAC) in Patients with Angina and Non-Obstructive Coronary Arteries (ANOCA)

The goal of this clinical trial is to determine if N-acetylcysteine (NAC) can reduce angina frequency in women with Angina with Non-Obstructive Coronary Arteries (ANOCA). It will also assess the impact of NAC on health status and quality of life. The main questions it aims to answer are:
(i) Does NAC reduce the number of angina episodes per week? (ii) How does NAC affect quality of life and symptom burden in ANOCA patients? (iii) Does NAC reduce the need for short-acting nitrate use?
Researchers will compare NAC to a placebo in a randomized, double-blind, placebo-controlled crossover study to determine its effectiveness.
Participants will receive treatment with NAC 600mg twice daily for 4 weeks (28 days) and matched placebo for 4 weeks (28 days) in a computer-generated random order giving a total dosing period of 8 weeks. There will be a 2-week washout between the two treatment periods.
The effectiveness of N-Acetylcysteine (NAC) will be assessed using the following measures:
Angina Diary: Participants will record the frequency and severity of their angina episodes.
Seattle Angina Questionnaire-7 (SAQ-7): Participants will complete this questionnaire to assess physical limitations, angina frequency, and quality of life.
EuroQol 5-Dimension (EQ-5D) Questionnaire: Participants will rate their overall health and quality of life.

Start Date01 Jun 2025

Sponsor / Collaborator

University of Adelaide

100 Clinical Results associated with Acetylcysteine

100 Translational Medicine associated with Acetylcysteine

100 Patents (Medical) associated with Acetylcysteine

38,165

Literatures (Medical) associated with Acetylcysteine

31 Dec 2025·Cell Adhesion & Migration

N-Acetylcysteine relieving hydrogen peroxide-induced damage in granulosa cells of sheep

Article

Author: Huo, Shengdong ; Zhao, Bingzhu ; Ding, Xiaona ; Yingpai, Zhaxi ; Zhang, Taojie ; Chen, Hao ; Yang, Chongfa ; Li, Yang ; Wang, Jine ; Zhao, Zhijie ; Yang, Yahua

Sheep ovarian granulosa cells (GCs) play a unique role in the ovary. Damage to GCs can affect the normal development of oocytes. The oxidative stress model was constructed by H₂O₂to study the biological changes. Specifically, pathological characteristic was assessed by immunohistochemistry (IHC), while signaling pathway was studied using western blot, quantitative RT-PCR, and immunofluorescence. Theresults showed that the oxidative damage model was successfully constructed by 200 μmol/LH₂O₂ for 12 h. NAC can protect the proliferation of GCs under H₂O₂-induced oxidative stress and reduce apoptosis. It can also promote the secretion of E₂ and P₄ by GCs and reduce the inflammatory response of GCs. NAC can enhance the expression of NRF2, PI3K and Akt. These findings suggest that NAC alleviates H₂O₂-induced oxidative stress injury through NRF2/PI3K/AKT signaling pathways. Provide ideas for studying the poor quality of mammalian oocytes.

31 Dec 2025·CANCER BIOLOGY & THERAPY

Long-term effects of neoadjuvant chemotherapy in variant histology locally advanced colon cancer: a propensity score-matched analysis

Article

Author: Wang, Zeshen ; Wang, Kuan ; Wang, Qiancheng ; Ju, Yuming ; Jin, Shiyang

PURPOSE:

Neoadjuvant chemotherapy (NAC) has proven valuable in treating locally advanced colon cancer (LACC) and is included as a treatment option for patients with clinical T4b colon cancer by the National Comprehensive Cancer Network. However, the long-term survival benefit of NAC in LACC remains debated, due to a lack of conclusive clinical trial results identifying the patients who would benefit most from NAC. This study aimed to assess the efficacy of NAC in patients with LACC based on histological subtype.

PATIENTS AND METHODS:

This retrospective study analyzed 3,709 patients with LACC who underwent curative resection at Harbin Medical University Cancer Hospital between 2014 and 2018. Patients were grouped into two groups: neoadjuvant chemotherapy (NAC) and adjuvant chemotherapy (AC) groups. Propensity score matching (PSM) was used to adjust for confounders, and survival outcomes of the two groups across different histological subtypes were evaluated using Kaplan-Meier (K-M) curves and log-rank tests.

RESULTS:

Patients with non-mucinous adenocarcinoma (NMAC) treated with NAC had a significantly improved 5-year OS rate (76.3% vs. 69.2%, p = .039) and DFS rate (67.2% vs. 60.1%, p = .041) compared with patients treated with AC. However, there was no significant difference in OS and DFS between the two treatment groups among patients with mucinous adenocarcinoma (MAC) and signet ring cell carcinoma (SRCC).

CONCLUSION:

In patients with LACC, the prognostic value of NAC varied by histology. NMAC may serve as a predictor of improved long-term survival benefit from NAC in these patients.

31 Dec 2025·JOURNAL OF INVESTIGATIVE SURGERY

Effects of Hsa-miR-4741/LILRB2 on Senescence of Nucleus Pulposus Cells and Their Prognostic Values in Lumbar Disc Herniation

Article

Author: Lin, Mingjian ; He, Zhendong ; Wang, Gang-Gang ; Zheng, Nan ; Guo, Xiu-Quan

BACKGROUND:

The incidence of lumbar disk herniation (LDH) is usually caused by lumbar disk degeneration. Surgery is a common treatment strategy for LDH, but it can recur, resulting in recurrent disk herniation (RDH).

PURPOSE:

To explore the predictive value of hsa-miR-4741 and LILRB2 in the prognosis of LDH surgery and the mechanism of nucleus pulposus senescence.

METHOD:

The ROC curves of RDH based on hsa-miR-4741 and LILRB2 were constructed to evaluate their predictive values in the prognosis of LDH surgery. Human nucleus pulposus cells (NPC) was treated by TNF-α to construct a cell senescence model, studying the senescence mechanism. Oxidative stress and senescence markers were detected after overexpression of hsa-miR-4741 and LILRB2 to evaluate their effects on the senescence of NPC. Dual luciferase assay and the transfection of hsa-miR-4741 mimics or inhibitor were used to investigate the targeted regulation of it to LILRB2.

RESULTS:

The combination of hsa-miR-4741 and LILRB2 showed higher accuracy in predicting the outcome of RDH (AUC = 0.9367), compared with a single molecule. Overexpression of hsa-miR-4741 enhanced TNF-α-induced oxidative stress and senescence, while LILRB2 overexpression had the opposite effect. Hsa-miR-4741 mimics attenuated the luciferase activity of NPC transfected with wt-LILRB2 vector and significantly down-regulated LILRB2 expression. In addition, the antioxidant NAC reversed the promotion of hsa-miR-4741 on NPC senescence.

CONCLUSION:

The combination of hsa-miR-4741 and LILRB2 was a good predictor of LDH prognosis. Hsa-miR-4741 promoted oxidative stress-induced NPC senescence by negatively regulating LILRB2.

News (Medical) associated with Acetylcysteine

02 Apr 2025

·www.prnewswire.com

Arctic Therapeutics research suggests preventative strategy against HCCAA

N-acetylcysteine (NAC) shows promise to treat hereditary cystatin C amyloid angiopathy (HCCAA) HCCAA – a subtype of cerebral amyloid angiopathy (CAA) – is an ultra-rare Icelandic amyloid disease due to a mutation in the CST3 gene encoding for the protease inhibitor, cystatin C. HCCAA causes cerebral hemorrhages in asymptomatic carriers of the L68Q variant due to amyloid aggregation with precipitation in brain vessels and tissue. Findings could guide the development of preventative therapies for related CAAs. REYKJAVIK, Iceland, April 2, 2025 /PRNewswire/ -- Icelandic drug discovery and development company Arctic Therapeutics (ATx) today announced the publication of research in JAMA Neurology, which informs a possible therapeutic strategy to treat a rare form of familial dementia. The publication, titled N-Acetylcysteine for hereditary cystatin C amyloid angiopathy (HCCAA), a nonrandomised clinical trial, details a new treatment approach for HCCAA, a rare and fatal genetic brain disorder that primarily affects young Icelandic adults, with the disease process beginning in childhood. The research provides insights into the potential of N-acetylcysteine (NAC) as a treatment for HCCAA, a disease with no currently approved therapeutic options. The study highlights how NAC may reduce disease-associated biomarkers and slow disease progression. The study is the first phase 2a clinical trial to assess the safety and therapeutic potential of high-dose NAC in patients carrying the L68Q-CST3 sequence variation of HCCAA. Results indicate that NAC is well tolerated, reduces disease specific biomarkers and stabilises disease progression, suggesting NAC may offer a preventative strategy against HCCAA. These findings could accelerate the development of preventative therapies for individuals at risk of HCCAA and other forms of CAAs. "These promising results provide hope to HCCAA patients and their families," Dr Ásbjörg Ósk Snorradóttir, lead author of the study explained. Senior author, Dr. Hákon Hákonarson, director of the Center for Applied Genomics at the Children's Hospital of Philadelphia and founder of Arctic Therapeutics added: "This study provides the first clinical evidence that NAC, by breaking disulfide bonds and other aberrant molecular interactions, can disrupt cystatin C oligomers and prevent amyloid aggregation that ultimately accumulates in brain vessels. By targeting the root biochemical process behind HCCAA pathology, NAC may ultimately offer a novel disease-modifying approach, not only for this devastating condition, but potentially for other forms of CAAs and protein aggregation disorders where toxic oligomers are central to disease progression." The open-label phase 2a clinical trial was conducted at Iceland's Landspitali University Hospital from March 2019 to December 2021. A total of 17 participants were enrolled, all confirmed carriers of the L68Q-CST3 mutation. The study assessed: Safety & tolerability: NAC was well tolerated, with no drug-related severe adverse events. Five participants experienced cerebral hemorrhages, but none resulted in permanent neurological damage. Biomarker reduction: Significant reductions were observed in collagen IV, fibronectin, vimentin, and SMAD levels—key indicators of disease progression. Plasma & skin biomarker changes: NAC was shown to increase reduced glutathione levels, a protective antioxidant, and reduce high-molecular-weight cystatin C aggregates, which are linked to amyloid buildup in the brain. Cognitive stability: No measurable decline in cognitive function was observed during the study period. Building on these findings, as well as internal in-vitro data that demonstrates that NAC-amide (NACA) has more than 10-fold higher potency in preventing or dispersing amyloid complex aggregates than NAC and increased ability to penetrate the blood brain barrier and get into cells involved in the disease pathogenesis, ATx has launched a European Medicines Agency-approved registration study to monitor safety, tolerability, and efficacy using NACA in patients with HCCAA. For more details, read the full study in JAMA Neurology: Original Investigation. About Arctic Therapeutics Arctic Therapeutics is an Icelandic drug discovery and development company established in 2015, which has licensed intellectual property from Children's Hospital of Philadelphia. ATx leverages the transformative power of applied genomics, steering the course of drug development towards safer, more effective treatments for some of the world's most challenging diseases. The company has operations in Iceland, the US and multiple collaborations across Europe. For more information, please visit: and follow us on LinkedIn For media inquires Gulli Arnason, Chief Strategy Officer [email protected] +354 660 0053 This information was brought to you by Cision The following files are available for download: WANT YOUR COMPANY'S NEWS FEATURED ON PRNEWSWIRE.COM? 440k+ Newsrooms & Influencers 9k+ Digital Media Outlets 270k+ Journalists Opted In GET STARTED

Phase 2Clinical Result

19 Mar 2025

·investor.cumberlandpharma.com

FIGHT DMD Trial Results Selected for Late-Breaking Presentation at MDA Clinical & Scientific Conference

Ifetroban demonstrated significant 5.4% improvement in cardiac function NASHVILLE, Tenn., March 19, 2025 /PRNewswire/ -- Cumberland Pharmaceuticals Inc. (Nasdaq: CPIX), a specialty pharmaceutical company with development efforts focused on rare diseases, today announced that results from its Phase 2 FIGHT DMD clinical trial were selected for a late-breaking presentation at the Muscular Dystrophy Association (MDA) Clinical & Scientific Conference in Dallas. The trial demonstrated significant cardiac benefits for patients with Duchenne muscular dystrophy (DMD), potentially addressing the leading cause of death in this devastating disease. The presentation, delivered today by Dr. John Jerry Parent, highlighted the breakthrough findings from Cumberland's study of ifetroban in DMD heart disease. For the abstract presented at the meeting, please see the MDA website. The Phase 2 FIGHT DMD trial demonstrated that high-dose ifetroban treatment resulted in a 3.3% improvement in left ventricular ejection fraction (LVEF) compared to placebo. When compared with propensity-matched natural history controls, the difference was even more pronounced, with high-dose treatment providing a significant 5.4% overall improvement in LVEF, as control patients experienced a 3.6% decline in LVEF. This improvement in cardiac function could translate to meaningful benefits in quality of life and survival for DMD patients. The complete presentation slides are now available on Cumberland's website. "The enthusiastic response from MDA conference attendees reinforces the importance of our work in targeting DMD-related heart disease," said John Jerry Parent, MD, Associate Professor of Clinical Pediatrics and Medical Director of the Pediatric Heart Transplant at Indiana University School of Medicine and Site Investigator at Riley Children's Hospital for the FIGHT DMD trial. "These findings represent a potential paradigm shift in how we approach cardiac complications in DMD patients." "We are honored that the MDA recognized the significance of our FIGHT DMD trial by selecting it for a late-breaking presentation," said A.J. Kazimi, Chief Executive Officer of Cumberland Pharmaceuticals. "This platform allowed us to share our promising results with the global DMD community, including leading researchers, clinicians and patient advocates who are working tirelessly to improve outcomes for those affected by this devastating disease." "These results offer hope to thousands of families affected by DMD," said Sharon Hesterlee, PhD, Chief Research Officer, MDA. "While current therapies focus on preserving muscle function, addressing the cardiac complications of DMD remains an urgent unmet need. Cumberland's work with ifetroban represents a critical step forward in potentially extending and improving the lives of DMD patients." Ifetroban, an oral thromboxane receptor antagonist, has received both Orphan Drug Designation and Rare Pediatric Disease Designation from the FDA for DMD-related heart disease. Cumberland has secured a growing portfolio of patents with claims associated with the product for this DMD indication. Next steps include further data analysis and completion of a full study report in preparation for an end-of-Phase-2 meeting with the FDA to determine next steps associated with the product's development and commercialization. For more information about the FIGHT DMD trial, please visit www.fightdmdtrial.com. About Duchenne muscular dystrophy (DMD) DMD is a rare and incurable pediatric disease caused by mutations in the gene encoding dystrophin, a protein critical for muscle function, including the heart. Patients with DMD slowly lose muscle function, resulting in the inability to walk, difficulty breathing and heart failure. While current treatments can help manage some DMD symptoms, there are no approved therapies specifically targeting DMD-related heart disease, highlighting a critical unmet medical need. About ifetroban Ifetroban is a once-daily oral medication that works by blocking the thromboxane receptor, which plays a key role in inflammation and fibrosis. The drug has received both Orphan Drug Designation and Rare Pediatric Disease Designation from the FDA, highlighting its potential significance in treating this devastating condition. If approved, ifetroban would be the first therapy specifically indicated for DMD-related heart disease. A previous study conducted at Vanderbilt University Medical Center demonstrated that ifetroban is protective against cardiomyopathy in several preclinical models of muscular dystrophy. The results of that study were published in the Journal of the American Heart Association (West 2019). Based on those promising results, Cumberland Pharmaceuticals became the first recipient of an FDA Office of Orphan Products Development clinical trial grant for DMD, funding the development of this Phase 2 clinical trial. References: Soslow JH, Xu M, Slaughter JC, et al. Cardiovascular Measures of All-Cause Mortality in Duchenne Muscular Dystrophy. Circ Heart Fail. 2023 Aug;16(8):e010040. doi: 10.1161/CIRCHEARTFAILURE.122.010040. Epub 2023 Jun 8. PMID: 37288563; PMCID: PMC10524475. West JD, Galindo CL, Kim K, et al. Antagonism of the thromboxane-prostanoid receptor as a potential therapy for cardiomyopathy of muscular dystrophy. J Am Heart Assoc. 2019;8(21):e011902. doi: 10.1161/JAHA.118.011902. About Cumberland Pharmaceuticals Cumberland Pharmaceuticals is the largest biopharmaceutical company founded and headquartered in Tennessee. The company is focused on providing unique products that improve the quality of patient care. Cumberland develops, acquires, and commercializes products for the hospital acute care, gastroenterology and oncology market segments. Cumberland's portfolio of FDA-approved brands includes: Acetadote® (acetylcysteine) injection, for the treatment of acetaminophen poisoning; Caldolor® (ibuprofen) injection, for the treatment of pain and fever; Kristalose® (lactulose) oral, a prescription laxative, for the treatment of constipation; Sancuso® (granisetron) transdermal, for the prevention of nausea and vomiting in patients receiving certain types of chemotherapy treatment; Vaprisol® (conivaptan) injection, to raise serum sodium levels in hospitalized patients with euvolemic and hypervolemic hyponatremia; and Vibativ® (telavancin) injection, for the treatment of certain serious bacterial infections including hospital-acquired and ventilator-associated bacterial pneumonia, as well as complicated skin and skin structure infections. In addition to this Duchenne muscular dystrophy program, the company also has Phase 2 clinical studies underway evaluating its ifetroban product candidate in patients with Systemic Sclerosis and Idiopathic Pulmonary Fibrosis. For more information on Cumberland's approved products, including full prescribing information, please visit the individual product websites, which can be found on the company's website: www.cumberlandpharma.com. Forward-Looking Statements This press release contains forward-looking statements, which are subject to certain risks and reflect Cumberland's current views on future events based on what it believes are reasonable assumptions. No assurance can be given that these events will occur. Forward-looking statements include, among other things, statements regarding the company's intent, belief or expectations, and can be identified by the use of terminology such as "may," "will," "expect," "believe," "intend," "plan," "estimate," "should," "seek," "anticipate," "look forward" and other comparable terms or the negative thereof. As with any business, all phases of Cumberland's operations are subject to factors outside of its control, and any one or combination of these factors could materially affect Cumberland's operation results. These factors include macroeconomic conditions, including rising interest rates and inflation, competition, an inability of manufacturers to produce Cumberland's products on a timely basis, failure of manufacturers to comply with regulations applicable to pharmaceutical manufacturers, natural disasters, public health epidemics, maintaining an effective sales and marketing infrastructure, and other events beyond the company's control as more fully discussed in its most recent annual report on Form 10-K as filed with the U.S. Securities and Exchange Commission ("SEC"), as well as the company's other filings with the SEC from time to time. There can be no assurance that results anticipated by the company will be realized or that they will have the expected effects. Readers are cautioned not to place undue reliance on forward-looking statements, which speak only as of the date hereof. The company does not undertake any obligation to publicly revise these statements to reflect events after the date hereof. View original content to download multimedia:https://www.prnewswire.com/news-releases/fight-dmd-trial-results-selected-for-late-breaking-presentation-at-mda-clinical--scientific-conference-302405491.html SOURCE Cumberland Pharmaceuticals Inc. Investor Contact: Shayla Simpson, Cumberland Pharmaceuticals, (615) 255-0068; Media Contact: Molly Aggas, Dalton Agency, (704) 641-6641

Clinical ResultPhase 2Orphan Drug

19 Mar 2025

·www.echemi.com

KYOWA HAKKO BIO Faces Import Suspension of Five Key APIs Amid Compliance Issues

On March 16, 2025, the National Medical Products Administration (NMPA) of China announced the suspension of imports from KYOWA HAKKO BIO CO., LTD. due to non-compliance with approved production protocols at its Hofu factory. This decision affects several active pharmaceutical ingredients (APIs) including glutathione, acetylcysteine, tryptophan, phenylalanine, and L-valine, which were found to be produced with unapproved methods such as outsourcing and improper labeling. The affected APIs are critical in various pharmaceutical applications. Glutathione, an essential antioxidant, is widely used for liver protection, detoxification, and as an adjunct in chemotherapy treatments. Acetylcysteine is commonly utilized for respiratory conditions, while tryptophan and phenylalanine are vital amino acids found in numerous dietary supplements and medications. L-valine plays a significant role in nutrition and drug synthesis. The NMPA's announcement indicates that these APIs failed to meet the necessary quality and production standards, leading to their classification as “I” in the regulatory review process, signifying they did not pass the required assessments for formulation production. As a result, all import permits for these products have been halted, impacting both the supply chain and market presence of KYOWA HAKKO BIO in China. Founded in 2008, KYOWA HAKKO BIO is a subsidiary of Kyowa Hakko Kogyo and has established itself as a leader in the global glutathione market, holding a significant share alongside competitors such as Shandong Jincheng Bio and KOHJIN Life Sciences. In 2023, the global glutathione market was valued at approximately $98 million, with KYOWA contributing substantially to this figure, particularly as China accounts for nearly 20% of its revenue. The implications of this suspension are far-reaching. Companies relying on these APIs for their formulations will face immediate supply shortages, which could lead to significant revenue losses and stockpile issues for KYOWA. Furthermore, the reputational damage incurred from this compliance failure may hinder future market expansion and partnerships. The NMPA has mandated that any formulations made with these suspended APIs must not be released into the market. Already marketed products containing these ingredients are subject to immediate investigation and risk assessment, with manufacturers required to implement necessary control measures. While domestic alternatives may mitigate some market pressures, the suspension poses a serious challenge to manufacturers dependent on imported raw materials. KYOWA HAKKO BIO must now focus on rectifying its production processes to regain compliance and restore its standing in the competitive pharmaceutical landscape. This incident serves as a stark reminder of the importance of regulatory adherence in the pharmaceutical industry, highlighting the potential consequences of failing to meet established standards. As the situation develops, the industry will be watching closely to see how KYOWA navigates this compliance crisis and its impact on the broader market.

100 Deals associated with Acetylcysteine

External Link

KEGG	Wiki	ATC	Drug Bank
D00221	Acetylcysteine	V03AB23 S01XA08 R05CB01	DB06151

R&D Status

Approved

10 top approved records.

to view more data

Indication	Country/Location	Organization	Date
Nails, Ingrown	Japan	Maruho Co., Ltd.	27 Mar 2023
Acetaminophen overdose	Australia	Pfizer Australia Pty Ltd.	17 Jul 2006
Pulmonary Disease, Chronic Obstructive	China	Jiangsu Jibeier Pharmaceutical Co. Ltd.	01 Jan 1985
Asthma	Japan	Sannova KK	05 Jan 1965
Bronchiectasis	Japan	Sannova KK	05 Jan 1965
Bronchitis, Chronic	Japan	Sannova KK	05 Jan 1965
Cystic Fibrosis	Japan	Sannova KK	05 Jan 1965
Laryngitis	Japan	Sannova KK	05 Jan 1965
Pharyngitis	Japan	Sannova KK	05 Jan 1965
Pneumonia	Japan	Sannova KK	05 Jan 1965
Pulmonary Emphysema	Japan	Sannova KK	05 Jan 1965
Pulmonary Tuberculosis	Japan	Sannova KK	05 Jan 1965
Chemical and Drug Induced Liver Injury	United States	Apothecon LLC	14 Sep 1963
Liver Injury	United States	Apothecon LLC	14 Sep 1963

Developing

10 top R&D records.

to view more data

Indication	Highest Phase	Country/Location	Organization	Date
Bronchitis	NDA/BLA	China	Zambon Switzerland Ltd.	21 Feb 2022
Acute Bronchitis	Phase 3	China	Zambon Switzerland Ltd.	21 Jun 2019
Acute Bronchitis	Phase 3	China	Zambon SpA	21 Jun 2019
Idiopathic Pulmonary Fibrosis	Phase 3	Belgium	Zambon SpA	01 Mar 2000
Idiopathic Pulmonary Fibrosis	Phase 3	France	Zambon SpA	01 Mar 2000
Idiopathic Pulmonary Fibrosis	Phase 3	Germany	Zambon SpA	01 Mar 2000
Idiopathic Pulmonary Fibrosis	Phase 3	Italy	Zambon SpA	01 Mar 2000
Idiopathic Pulmonary Fibrosis	Phase 3	Netherlands	Zambon SpA	01 Mar 2000
Idiopathic Pulmonary Fibrosis	Phase 3	Spain	Zambon SpA	01 Mar 2000
Idiopathic Pulmonary Fibrosis	Phase 3	United Kingdom	Zambon SpA	01 Mar 2000

Clinical Result

Indication

Phase

Evaluation

View All Results

Study	Phase	Population	Analyzed Enrollment	Group	Results	Evaluation	Publication Date


AACR2025	Not Applicable	Hematologic Neoplasms H3 \| γ-H2A.X \| GSH	-	N-acetyl-L-cysteine (NAC)	ilzgzvqliu(fzdhmyutiq) = sctpfgokbn sdxlzezelo (nnsshvplyh )	Positive	29 Apr 2025
				Psammaplin A (PsA)	ilzgzvqliu(fzdhmyutiq) = ihzfhgiwud sdxlzezelo (nnsshvplyh )
NCT00585559 (CTgov)	Phase 3	Aneurysm, Intracranial Berry, 1 \| Vasospasm, Intracranial	44	N-acetylcysteine (N-acetylcysteine IV Infusion at 0.5 gm Hourly)	wfbdrpgflo(axdgzhbedv) = ztirqilckm bvkjblpxje (njezanvmkz, gafidwcdkt - nqfwfcglqk) View more	-	18 Apr 2025
				Placebo+N-acetylcysteine (Placebo for N-acetylcysteine IV Infusion at 0.5 gm Hourly)	wfbdrpgflo(axdgzhbedv) = imebeiclfw bvkjblpxje (njezanvmkz, rwxvpakuwd - jwhtuduofu) View more
NCT03306979 (CTgov)	Phase 2	Cognitive Dysfunction	60	N Acetylcysteine (N-acetylcysteine)	aelokfkeuc(duqekxptqq) = hmgzcvrhvq kbcftcpdls (vsicernimz, hntosjqqhr - uutktkxqyi) View more	-	26 Mar 2025
				Placebo oral capsule (Placebo)	aelokfkeuc(duqekxptqq) = ilbxvcdakw kbcftcpdls (vsicernimz, cbpzwwmccb - yhqceshyaz) View more
NCT04766450 (Pubmed \| Diabetol Metab Syndr)	Phase 4	Diabetic peripheral neuropathy Adjuvant Glutathione peroxidase \| NRF-2 \| TNF	-	N-acetyl cysteine 2400 mg/day	mcgvnothhs(vtacikglgo) = xqzwgxtvzk rezxawsiel (tqrhbyuvnd ) View more	Positive	04 Mar 2025
NCT03707951 (CTgov)	Phase 2	Alcohol Use Disorder	126	N-acetylcysteine (N-acetylcysteine)	maugbucqkp(vihlsgmiwb) = dyendvisec bblwcoyfsw (hpwbbqhdpc, 28.3) View more	-	08 Jan 2025
				Placebo oral capsule (Placebo)	maugbucqkp(vihlsgmiwb) = lsazfxeper bblwcoyfsw (hpwbbqhdpc, 43.1) View more
Pubmed Manual	Not Applicable	Pulmonary Disease, Chronic Obstructive	91,546	N-acetylcysteine (NAC) users	jtaxfcwzwu(lvaguhvnsz) = wqeoazclfp xlkeatxbzb (ijuobonacc )	Positive	01 Jan 2025
				Non-NAC users	jtaxfcwzwu(lvaguhvnsz) = mloavwdqhj xlkeatxbzb (ijuobonacc )
NCT03055377 (CTgov)	Phase 2/3	Cannabis withdrawal	192	N-Acetyl Cysteine (N-acetylcysteine)	hvlndxplhw = enqhnkfhwn thieqqpoxz (txcwaefhjm, musznaabbe - gkxcqhoiug) View more	-	17 Dec 2024
				Placebo oral capsule (Placebo)	hvlndxplhw = dosrxuaueg thieqqpoxz (txcwaefhjm, jugisivubu - azlenxlifo) View more
DEEPSARC (ESMO_ASIA2024)	Not Applicable	Soft Tissue Sarcoma Adjuvant \| Neoadjuvant	8,331	Adjuvant Chemotherapy (AC)	zhcjvgmmyz(gcwculxinh) = kesaavffaf gnjnyqhrkw (wpqhjnjhok, 47 - 54)	Negative	07 Dec 2024
				Neoadjuvant Chemotherapy (NAC)	zhcjvgmmyz(gcwculxinh) = mzbcxkarcf gnjnyqhrkw (wpqhjnjhok, 61 - 64)
NCT00558142 (CTgov)	Phase 4	Kidney Diseases	107	placebo+Acetylcysteine (Healthy Volunteers, no Contrast)	tjajydgaza(kuntvrpjqo) = ahwzxfigwb nndabzbzep (vgqrhgbsze, mswqbnjovy - tpyibjdfgk) View more	-	19 Sep 2024
				placebo+Acetylcysteine (Volunteers With CKD III, no Contrast)	tjajydgaza(kuntvrpjqo) = wvajqbysdf nndabzbzep (vgqrhgbsze, muoawvrgmu - crhyjakzlk) View more
NCT03253328 (CTgov)	Early Phase 1	Chronic Limb-Threatening Ischemia \| Diabetes Mellitus \| Leg Injuries	33	Active Arm N-acetyl cysteine (NAC) (Active Arm N-acetyl Cysteine (NAC))	ofbscexujz(nnhurhezlw) = sgdqeinpxq lyfrilbvcg (nduwnmgmua, 0.056) View more	-	16 Aug 2024
				Placebo Arm (Placebo Arm)	ofbscexujz(nnhurhezlw) = cxtdimxpyp lyfrilbvcg (nduwnmgmua, 0.117) View more

Translational Medicine

Boost your research with our translational medicine data.

view full example data

Deal

Boost your decision using our deal data.

view full example data

Core Patent

Boost your research with our Core Patent data.

view full example data

Clinical Trial

Identify the latest clinical trials across global registries.

view full example data

Approval

Accelerate your research with the latest regulatory approval information.

view full example data

Regulation

Understand key drug designations in just a few clicks with Synapse.

view full example data

Chat with Hiro

Get started for free today!

Accelerate Strategic R&D decision making with Synapse, PatSnap’s AI-powered Connected Innovation Intelligence Platform Built for Life Sciences Professionals.

Start your data trial now!

Synapse data is also accessible to external entities via APIs or data packages. Empower better decisions with the latest in pharmaceutical intelligence.

Bio

Bio Sequences Search & Analysis

Chemical

Chemical Structures Search & Analysis